GlassScriptPhysician profile
Emily Lau
NPI 1811596927
$2,829.40
in general payments reported to CMS, 2019-2025
35 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $378 · 2022: $494 · 2023: $346 · 2024: $373 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,957.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $461.35 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $447.91 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $289.74 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $193.70 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $151.84 | 2025 | Veozah |
| Lilly USA, LLC | $135.81 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Corium, LLC | $133.28 | 2022-2024 | Azstarys |
| Abbott Laboratories | $132.82 | 2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $90.48 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $66.75 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $60.80 | 2021 | |
| Gilead Sciences, INC. | $53.10 | 2025 | |
| Dexcom, INC. | $50.68 | 2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.99 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.29 | 2021-2025 | Xifaxan |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $40.66 | 2022 | |
| Genentech USA, INC. | $37.25 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.68 | 2021 | |
| Merck Sharp & Dohme LLC | $31.10 | 2021-2022 | |
| Axsome Therapeutics, INC. | $29.92 | 2025 | Auvelity |
| Inari Medical, INC. | $27.73 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Pfizer INC. | $24.61 | 2025 | |
| Inspire Medical Systems, INC. | $24.33 | 2025 | Inspire |
| Siemens Medical Solutions USA, INC. | $22.95 | 2022 | |
| Phathom Pharmaceuticals, INC. | $22.09 | 2024 | Voquezna |
| Esperion Therapeutics, INC. | $21.16 | 2021 | |
| Avion Pharmaceuticals | $20.01 | 2022 | |
| Jazz Pharmaceuticals INC. | $19.30 | 2021 | |
| Medtronic, INC. | $18.44 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $18.40 | 2025 | Rexulti |
| Eisai INC. | $16.94 | 2021 | |
| Biogen, INC. | $16.83 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.01 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.74 | 2023 | Quviviq |
| Clarus Therapeutics INC. | $13.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Lau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.